4/16
05:20 pm
zlab
A Risky Bet: Zai Lab's Uncertain Future [Seeking Alpha]
Medium
Report
A Risky Bet: Zai Lab's Uncertain Future [Seeking Alpha]
4/15
07:30 am
zlab
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Low
Report
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
4/11
07:37 am
zlab
Zai Lab Statement on Executive Management Team's Agreement on Share Activities [Yahoo! Finance]
Medium
Report
Zai Lab Statement on Executive Management Team's Agreement on Share Activities [Yahoo! Finance]
4/11
07:30 am
zlab
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
Medium
Report
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
4/2
07:39 am
zlab
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs [Yahoo! Finance]
Low
Report
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs [Yahoo! Finance]
4/2
07:30 am
zlab
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
Low
Report
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
4/1
11:47 am
zlab
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago [Yahoo! Finance]
Medium
Report
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago [Yahoo! Finance]
4/1
07:38 am
zlab
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... [Yahoo!
Low
Report
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... [Yahoo!
4/1
07:30 am
zlab
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
Medium
Report
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
3/27
09:40 am
zlab
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer [Yahoo! Financ
Neutral
Report
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer [Yahoo! Financ
3/27
09:29 am
zlab
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Low
Report
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
3/27
07:58 am
zlab
Novocure climbs after late-stage win for lung cancer therapy [Seeking Alpha]
Low
Report
Novocure climbs after late-stage win for lung cancer therapy [Seeking Alpha]
3/13
07:22 pm
zlab
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors [Yahoo! Finance]
Medium
Report
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors [Yahoo! Finance]
3/13
07:05 pm
zlab
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
Medium
Report
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
3/6
04:10 pm
zlab
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) [Yahoo! Finance]
Medium
Report
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) [Yahoo! Finance]
3/6
04:01 pm
zlab
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
Medium
Report
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
3/6
07:30 am
zlab
Zai Lab Announces Participation in March Investor Conference
Low
Report
Zai Lab Announces Participation in March Investor Conference
3/1
10:24 am
zlab
argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
12:33 pm
zlab
Zai Lab Limited (NASDAQ: ZLAB) had its price target lowered by analysts at Citigroup Inc. from $123.00 to $66.00. They now have a "buy" rating on the stock.
Low
Report
Zai Lab Limited (NASDAQ: ZLAB) had its price target lowered by analysts at Citigroup Inc. from $123.00 to $66.00. They now have a "buy" rating on the stock.
2/29
09:06 am
zlab
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
01:03 am
zlab
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]
Low
Report
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]
2/27
04:49 pm
zlab
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results [Yahoo! Finance]
2/27
04:36 pm
zlab
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates [Yahoo! Finance]
Medium
Report
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates [Yahoo! Finance]
2/27
04:05 pm
zlab
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
Medium
Report
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
2/22
07:16 am
zlab
NovoCure GAAP EPS of -$0.45 beats by $0.07, revenue of $133.78M in-line [Seeking Alpha]
Low
Report
NovoCure GAAP EPS of -$0.45 beats by $0.07, revenue of $133.78M in-line [Seeking Alpha]